Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- pitolisant
- Raxar (grepafloxacin)
Interactions between your drugs
grepafloxacin pitolisant
Applies to: Raxar (grepafloxacin), pitolisant
CONTRAINDICATED: Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.
MANAGEMENT: Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.
References (7)
- Thomas M, Maconochie JG, Fletcher E (1996) "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol, 41, p. 77-81
- (2001) "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome
- Lode H, Vogel F, Elies W (1999) "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther, 21, p. 61-74
- Ball P (2000) "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother, 45, p. 557-9
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lumryz
Lumryz (sodium oxybate) is used for the treatment of patients with narcolepsy. Includes Lumryz side ...
Xywav
Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Sunosi
Sunosi (solriamfetol) is a prescription medicine used for the treatment of excessive sleepiness in ...
Adderall
Adderall (amphetamine and dextroamphetamine) is used to treat narcolepsy and ADHD. Includes side ...
Concerta
Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity ...
Ritalin
Ritalin (methylphenidate) is used to treat attention deficit disorder (ADD) and narcolepsy ...
Armodafinil
Armodafinil may be used to improve wakefulness in adults who are very sleepy due to narcolepsy ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.